M-128
Mirtazapine solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C17H19N3
CAS Number:
Molecular Weight:
265.35
EC Number:
UNSPSC Code:
41116107
NACRES:
NA.24
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
SMILES string
CN1CCN2C(C1)c3ccccc3Cc4cccnc24
InChI
1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
InChI key
RONZAEMNMFQXRA-UHFFFAOYSA-N
Gene Information
human ... ADRA2A(150) , ADRA2B(151) , ADRA2C(152) , HTR2A(3356) , HTR2C(3358)
General description
Mirtazapine is a tetracyclic antidepressant marketed under the trade names Remeron®, Avanza, or Zispin for treatment of depression. This Certified Spiking Solution® is suitable for LC/MS or GC/MS applications in forensic analysis, clinical toxicology, or urine drug testing.
Application
- Mirtazapine research solution for CNS studies: A study on the nose-to-brain delivery of mirtazapine via lipid nanocapsules highlights its potential for enhanced CNS targeting, offering a promising approach for treating neurological conditions. This method aims to improve the bioavailability and therapeutic effectiveness of mirtazapine, showcasing its utility in pharmacokinetic research and CNS depressant studies (Ibrahim et al., 2024).
- Mirtazapine liquid formulation for orally disintegrating tablets: Research into developing a novel direct compressible co-processed excipient for the formulation of mirtazapine orally disintegrating tablets emphasizes its importance in enhancing patient compliance and dosing accuracy. This study demonstrates mirtazapine′s role in pharmaceutical formulations, ensuring rapid onset of action which is critical in acute management of depressive episodes (Loke et al., 2024).
- High-purity mirtazapine liquid for neurotransmitter research: A review linking stress, depression, and insulin resistance explores the systemic effects of chronic inflammation and the role of treatments like mirtazapine. This research underscores the importance of mirtazapine in understanding the biochemical pathways involved in chronic mental health disorders and their somatic comorbidities (Mehdi et al., 2023).
- Stable mirtazapine formulation for opioid withdrawal treatment: Mirtazapine is explored as a one-stop strategy for the treatment of opioid withdrawal symptoms, highlighting its efficacy in reducing withdrawal severity and potentially lowering the dependency on traditional opioid replacement therapies. This application provides insights into mirtazapine′s versatility in treating complex drug dependencies (Lalani et al., 2023).
- Mirtazapine aqueous solution for pharmacokinetic profiling: Research on the simultaneous separation and determination of several chiral antidepressants, including mirtazapine, in wastewater by two-dimensional liquid chromatography offers critical insights into environmental exposure and bioaccumulation risks. This study is pivotal for environmental safety and pharmaceutical dispersion monitoring, reflecting mirtazapine′s impact beyond clinical settings (Zhong et al., 2023).
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Remeron is a registered trademark of MSD
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
related product
Product No.
Description
Pricing
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Target Organs
Eyes
Storage Class Code
3 - Flammable liquids
WGK
WGK 1
Flash Point(F)
49.5 °F - closed cup
Flash Point(C)
9.7 °C - closed cup
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Seda G Sagdinc et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 104, 222-234 (2012-12-26)
Mirtazapine (±)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine is a compound with antidepressant therapeutic effects. It is the 6-aza derivative of the tetracyclic antidepressant mianserin (±)-2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine. The FT-IR and FT-Raman spectra of mirtazapine have been recorded in 4000-400 cm(-1) and 3500-10 cm(-1), respectively. The optimized geometry
Xiaoyu Liu et al.
Neurochemical research, 38(9), 1973-1979 (2013-07-10)
Chemotherapic drugs may elicit acute or chronic peripheral neuropathies. Mirtazapine, as an antidepressant, is also used for the treatment of neuropathic pain. The current study aimed to investigate the effect of mirtazapine on the oxaliplatin-induced neuropathy in rats as well
Steven M Graves et al.
Pharmacology & therapeutics, 136(3), 343-353 (2012-09-11)
Understanding substance use disorders (SUDs) and the problems associated with abstinence has grown in recent years. Nonetheless, highly efficacious treatment targeting relapse prevention has remained elusive, and there remains no FDA-approved pharmacotherapy for psychostimulant dependence. Preclinical and clinical investigations assessing
E L Theunissen et al.
Clinical pharmacology and therapeutics, 93(6), 493-501 (2013-04-17)
The aim of this study was to assess the effects of a novel antidepressant, vortioxetine 10 mg, on driving, cognitive, and psychomotor performance in 24 healthy subjects in a double-blind, placebo-controlled, three-way crossover design. Mirtazapine 30 mg was included as an active
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial.
Renee Romeo et al.
The British journal of psychiatry : the journal of mental science, 202, 121-128 (2012-12-22)
Depression is a common and costly comorbidity in dementia. There are very few data on the cost-effectiveness of antidepressants for depression in dementia and their effects on carer outcomes. To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service